November 30, 2007

interceptCS Featured in Syndicated National Column

BURLINGTON, ON, - The Jenex Corporation (TSX Venture Exchange: JEN;

Frankfurt: JNX -at Yahoo Finance, use JEN.V) announced that interceptCS, the first product clinically proven and approved to prevent cold sores was featured in Dr. Gifford-Jones column. Dr. Gifford-Jones column appears in 52 newspapers across Canada. A copy of the article can be obtained at www.edmontonsun.com/Lifestyle/Health/2007/11/24/4681630-sun  or www.torontosun.com/Lifestyle/2007/11/24/4681496-sun

Jenex Director of Sales and Marketing, Michael Mayo commented: ”We are excited that exposure from this article will greatly increase the product awareness for interceptCS. This article along with the article in the December issue of Canadian Living magazine will help inform cold sore sufferers there is now a PREVENTION solution to their problem.”

About The Jenex Corporation:  Jenex has a non-invasive Medical Device that prevents cold sore outbreaks. The interceptCS™ Cold Sore Prevention System is approved in Canada and has received CE approval for European Union countries.  In addition to interceptCS, Jenex markets Therapik® for insect stings & bites. Therapik® immediately relieves the pain & itch caused by over 20,000 different insects. Therapik® is approved in Canada and the United States and Australia, as well as having CE Mark approval in the European Union countries.

Jenex's Thermal Therapy technology is patented in the U.S., Canada, Australia, & Europe.

Check www.interceptCS.com and www.JenexCorp.com for details.

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.

For further information

The Jenex Corporation, Michael A. Jenkins,

(905) 632-3830, Jenex@JenexCorp.com